⚡ Syringe Tool
Growth Hormone Secretagogue FDA Approved (Specific Indications) PubChem CID: 16137828

Tesamorelin: Clinical Mechanism, Dossier & Protocols

Stabilized synthetic GHRH analog with a trans-3-hexenoyl group that potently reduces visceral adipose tissue (VAT) and improves lipid and cognitive profiles.

Reconstitution Guide Syringe Calculator BAC Water Guide

🔬 Molecular Architecture & Physical Specifications

Molecular Weight
5135.9 g/mol
Chemical Formula
C221H366N72O67S
CAS Registry Number
218949-48-5
Elimination Half-Life
Approx. 26 - 38 minutes
Administration Route
Subcutaneous (SC)
NCBI PubChem Record
Amino Acid Sequence: Hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

⚙️ Primary Mechanism of Action

Acts on pituitary GHRH receptors to drive the synthesis and secretion of endogenous growth hormone, specifically activating lipolytic cascades that target visceral belly fat while sparing subcutaneous fat.

💉 Research Dosage & Reconstitution Standard

Requires pharmaceutical-grade 0.9% benzyl alcohol Bacteriostatic Water to inhibit bacterial replication for multi-dose access.

Full Step-by-Step Guide →
Standard Vial Sizes
2mg, 10mg
Target Research Dose
1mg to 2mg daily SubQ
Administration Frequency
Once daily before bed (fasted)
💧 Dilution Standard: Reconstitute with sterile Bacteriostatic Water for Injection (USP). Aim stream gently along the vial glass wall to avoid foaming. Store reconstituted solution at 2°C to 8°C (36°F to 46°F) protected from light. Discard multi-dose punctured vials at 28 days pursuant to USP <797> standards. Never freeze reconstituted liquid.

⚠️ Contraindications & Documented Adverse Effects

Strict Contraindications

  • Active malignancy
  • Disruption of hypothalamic-pituitary axis
  • Pregnancy

Documented Side Effects

  • Injection site erythema / itching
  • Peripheral edema (mild fluid retention)
  • Joint/muscle stiffness in early weeks

📚 Peer-Reviewed References & Authoritative Sources

Citations indexed in PubMed, National Center for Biotechnology Information (NCBI), and ClinicalTrials.gov.

1 VERIFIED CITATIONS
New England Journal of Medicine (NEJM 2007; 357:2359-2370)
Double-blind, placebo-controlled Phase 3 trial showing sustained 15.2% reduction in visceral fat with significant improvements in lipid profiles.
PMID: 18057337 · DOI: 10.1056/NEJMoa072375

Explore Related Research Modules

Access exact dilution guides, syringe unit calculators, and purity certificates for Tesamorelin.

💧 Tesamorelin Dilution Guide ⚡ Syringe Reconstitution Tool Bacteriostatic Water Monograph Tested Vendor Directory Cycle Cost Calculator